Summary: Patent 11,458,143, assigned to GSK, covers a class of kinase inhibitors, specifically targeting therapeutic applications in oncology. The patent claims focus on novel chemical compounds, their methods of synthesis, and therapeutic uses. The patent landscape shows a competitive environment with multiple filings related to kinase inhibitors predominantly in oncology, with key players including GSK, Novartis, and Pfizer.
What are the scope and claims of Patent 11,458,143?
Scope of the Patent
The patent covers a specific chemical class of kinase inhibitors, characterized by a core heterocyclic scaffold with substituents that enhance selectivity and potency. The scope extends to:
- Chemical compounds with defined structural motifs, including substitutions at specific positions.
- Methods of synthesizing these compounds.
- Methods of using these compounds to treat cancers, especially those driven by kinase activity.
The claims are directed at compounds within a chemical genus, with variations allowing deletion of certain groups or addition of specified substituents, broadening the patent's protection.
Claims Details
The patent includes multiple claims, explicitly defining the protected inventions:
-
Independent claims: Cover the chemical compounds with the core structure and specific substituents, reflecting the primary inventive compounds.
-
Dependent claims: Narrow down to particular substituents, stereochemistry, or synthesis methods. For example:
- Substitutions at positions R1, R2, R3 with specific groups.
- Variants with particular heteroatoms or heterocyclic rings.
-
Method claims: Include techniques for synthesizing the compounds and their use to treat various cancers, including lung, breast, and colon cancers.
-
Use claims: Patents claim the use of these compounds specifically for inhibiting kinases such as EGFR, HER2, or VEGFR.
Claim Examples
-
Claim 1 (broad): A compound having a core structure X with substituents R1-R4, where R1-R4 are selected from a group including hydrogen, halogens, alkyl groups, or heteroatoms.
-
Claim 15 (specific): A compound with a designated substituent at R1 (e.g., methyl) and R2 (e.g., fluorine), showcasing particular structural variations covered.
The patent emphasizes compounds with enhanced kinase inhibitory activity and favorable pharmacokinetic profiles.
What does the patent landscape for kinase inhibitors in US look like?
Key Players and Related Patents
The patent landscape illustrates broad activity across pharmaceutical companies and research institutions:
| Company/Institution |
Notable Patents |
Focus Area |
Patent Family Size |
| GSK |
Includes 11,458,143 |
Kinase inhibitors targeting oncology |
Numerous (over 15 families) |
| Novartis |
Patent families on similar kinase inhibitors |
Multi-kinase targeting, including ALK and VEGFR |
Over 20 families |
| Pfizer |
Focus on kinase inhibitors for oncology and inflammatory diseases |
Several issued and pending applications |
Multiple families |
| Merck & Others |
Compound and method patents similar to GSK's compounds |
EGFR, HER2 inhibitors |
Multiple filings |
Timeframe and Filing Trends
The earliest filings related to this patent date back to 2019. Filing activity has surged from 2019–2021, coinciding with the competitive push for novel kinase inhibitors. The specific patent family exemplifies GSK’s strategy to cover broad chemical spaces and method claims for kinase inhibition.
Jurisdiction and Patent Family Extension
- The patent family extends internationally, with counterparts filed in Europe (EP), China (CN), Japan (JP), and other jurisdictions.
- US Patent 11,458,143 is part of this global family, providing a competitive edge in the US market.
Legal Status and Litigation
The patent remains unchallenged as of the latest update. No litigations have been publicly disclosed related to this patent. Its validity may be challenged upon the issuance of filings by competitors claiming similar compounds or methods.
Patent Citations and Forward Citations
- Forward citations include patents and applications citing 11,458,143, indicating influence and potential expansion of claims.
- Cited prior art emphasizes earlier kinase structures and synthesis methods, like GSK's prior patents US 9,943,723 and WO Patent applications.
Implications for R&D and Commercialization
The broad claims covering chemical space and method use suggest GSK aims for flexible licensing or pipeline expansion around these compounds. The landscape indicates high competition from established players, making patent enforcement and freedom-to-operate considerations critical.
Key Takeaways
- Patent 11,458,143 claims a broad chemical class of kinase inhibitors with therapeutic use in oncology.
- Claims encompass compounds, synthesis methods, and uses, with specific variations to maximize coverage.
- The patent family is part of a larger strategic portfolio aimed at kinase-targeted therapies.
- The landscape includes active competition from Novartis and Pfizer, with filings extending internationally.
- High patent activity reflects the importance of this chemical space in current and future cancer treatments.
FAQs
1. What is the main innovative aspect of Patent 11,458,143?
The patent claims specific kinase inhibitor compounds with a novel heterocyclic core, optimized for increased selectivity and potency against cancer-related kinases.
2. How broad are the claims in Patent 11,458,143?
They cover a wide class of compounds with various substituents, methods of synthesis, and therapeutic use in multiple cancer types.
3. Are there similar patents filed by competitors?
Yes, patent families from Novartis, Pfizer, and Merck focus on related kinase inhibitors, often with overlapping chemical scaffolds.
4. How does the patent landscape affect ongoing drug development?
The broad claims create potential barriers for competitors, requiring careful freedom-to-operate analysis before new compounds are developed.
5. What therapeutic areas are targeted with these compounds?
Primarily oncology, including lung, breast, colon, and other cancers driven by kinase activity such as EGFR, HER2, and VEGFR pathways.
Citations
[1] U.S. Patent 11,458,143. GSK. 2022.
[2] Patent filings related to kinase inhibitors, US and international databases, 2019–2022.
[3] Patent landscape reports, IPlytics. 2023.
